Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchCurcuminCurcumin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis       

Curcumin as adjuvant Therapy in Mild - Moderate Covid 19

Kartika et al., ICE on IMERI, 2021
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Hospitalization time 41% Improvement Relative Risk Curcumin for COVID-19  Kartika et al.  LATE TREATMENT Is late treatment with curcumin beneficial for COVID-19? Retrospective 246 patients in Indonesia (January - June 2021) Shorter hospitalization with curcumin (p=0.048) c19early.org Kartika et al., ICE on IMERI, 2021, Jan 2022 Favorscurcumin Favorscontrol 0 0.5 1 1.5 2+
Curcumin for COVID-19
15th treatment shown to reduce risk in February 2021, now with p = 0.0000000096 from 27 studies.
No treatment is 100% effective. Protocols combine treatments.
5,100+ studies for 112 treatments. c19early.org
Retrospective 246 hospitalized patients in Indonesia, 136 treated with curcumin, showing shorter hospitalization time with treatment. All patients received vitamin C, D, and zinc.
This is the 12th of 27 COVID-19 controlled studies for curcumin, which collectively show efficacy with p=0.0000000096 (1 in 104 million).
21 studies are RCTs, which show efficacy with p=0.0000022.
hospitalization time, 41.0% lower, relative time 0.59, p = 0.048, treatment 139, control 107.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kartika et al., 28 Jan 2022, retrospective, Indonesia, preprint, 6 authors, study period January 2021 - June 2021.
This PaperCurcuminAll
CURCUMIN AS ADJUVANT THERAPY IN MILD-MODERATE COVID 19
Ronald Winardi Kartika, Marcel Tendean, Bernard Jonathan Christian, Katarina Dewi Sartika, Eka Widrian Suradji, Irsan Hasan, Ronald Winardi Kartika
Background: Coronavirus (Covid-19) has spread rapidly to more than 200 countries, including Indonesia. Adjuvant therapy of Vitamin C, D, Zinc has become beneficial for Covid-19 treatment to improve the immune system, while Curcumin is still not standard therapy. Curcumin can stimulate specific immune cells and can reduce oxidative stress. There is currently no scientific evidence showing that the addition of Curcumin can protect COVID-19, especially as an anti-inflammation and anticoagulant effect. Methods: This cross-sectional study was conducted at Ukrida Hospital from January -June 2021. The inclusion criteria are Mild-Moderate Covid-19 use on Curcumin and Supplement therapy ( Vitamin C, Vitamin D, and zinc). Data analyses with SPSS v.20 use Anova test and Kruskall Walis test. This study had been approved by The Institutional Board of the Faculty of Medicine Universitas Krida Wacana, Indonesia (No. 1053/SLKE-IM/UKKW/FKIK/KE/II/2021). Research Objectives: To see the effect of Curcumin as an additional therapy from Covid-19 by clinical and laboratory inflammation indicators of the usefulness of Curcumin are such as ratio neutrophil/lymphocyte, ratio platelet/lymphocyte, erythrocyte sedimentation rate (ESR), C-Reactive Protein ( CRP), and D Dimer. Results: There were 246 cases, with 62.6% male and 56.5% female taking Curcumin. Curcumin has a good effect in reducing inflammation and coagulation in mild-moderate Covid-19. Patient who got Curcumin or without Curcumin as additional supplement therapy shows patient that got Curcumin has decreased inflammatory markers N/L ratio (p = 0.041), P/L ratio (p = 0.040), ESR (p = 0.013 ), and CRP ( p= 0.045). Curcumin also has an anticoagulant effect that shows a decrease of D-Dimer ( p= 0.020). Conclusion: Curcumin is beneficial in mild-moderate Covid-19 as an anti-inflammatory and anticoagulant.
References
Aggarwal, Harikumar, Potential Therapeutic Effects of Curcumin, the Antiinflammatory Agent, Against Neurodegenerative, Cardiovascular, Pulmonary, Metabolic, Autoimmune and Neoplastic Diseases, Int. J. Biochem. Cel Biol
Anand, Kunnumakkara, Newman, Aggarwal, Bioavailability of Curcumin: Problems and Promises, Mol. Pharmaceutics
Biswas, Rahman, Modulation of Steroid Activity in Chronic Inflammation: a Novel Anti-inflammatory Role for Curcumin, Mol. Nutr. Food Res
Conti, Caraffa, Gallenga, Ross, Kritas et al., IL-1 Induces Throboxane-A2 (TxA2) in COVID-19 Causing Inflammation and Micro-thrombi: Inhibitory Effect of the IL-1 Receptor Antagonist (IL-1Ra), J. Biol. Regul. Homeost Agents
De Almeida Alvarenga, Leal, Borges, Silva De Aguiar, Faxén-Irving et al., Curcumin -A Promising Nutritional Strategy for Chronic Kidney Disease Patients, J. Funct. Foods
Ghosh, Gehr, Ghosh, Curcumin and Chronic Kidney Disease (CKD): Major Mode of Action through Stimulating Endogenous Intestinal Alkaline Phosphatase, Molecules
Gupta, Patchva, Aggarwal, Therapeutic Roles of Curcumin: Lessons Learned from Clinical Trials, Aaps J
Han, The Effects of Black Pepper on the Intestinal Absorption and Hepatic Metabolism of Drugs, Expert Opin. Drug Metab. Toxicol
Hewlings, Kalman, Curcumin: A Review of its Effects on Human Health, Foods
Huang, Wang, Li, Ren, Zhao et al., Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China, The Lancet
Keihanian, Saeidinia, Bagheri, Johnston, Sahebkar et al., Hemostasis, Thrombosis, and Coagulation, J. Cel Physiol
Kim, Ku, Bae, Anticoagulant Activities of Curcumin and its Derivative, BMB Rep
Leong, The Spice for Hypertension: Protective Role of Curcumin Longa, Biomed. Pharmacol. J
Liu, Ying, The Inhibitory Effect of Curcumin on Virus-Induced Cytokine Storm and its Potential Use in the Associated Severe Pneumonia, Front Cel Dev Biol
Loeber, Buechner, Dissertatio Inauguralis Medica de Curcumin Officinarum Ejusque Genuinis Virtutibus
Matthew, Fadus, Lau, Bikhchandani, Lynch, Curcumin: An age-old anti-inflammatory and anti-neoplastic agent, Journal of Traditional and Complementary Medicine
Maurya, Kumar, Prasad, Bhatt, Saxena, Structure-based Drug Designing for Potential Antiviral Activity of Selected Natural Products from Ayurveda against SARS-CoV-2 Spike Glycoprotein and its Cellular Receptor, VirusDis
Nguyen Ninh, Chinn, Ferrante, Kirby, Hohmann et al., Male gender is predictor of higher mortality in hospitalized adult with Covid-19, Plos One
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit